Navigation Links
Max Nutrition, Inc. Completes Share Exchange with American Spring Pharmaceutical, Inc.

NEW YORK, Jan. 31 /Xinhua-PRNewswire-FirstCall/ -- Max Nutrition Inc. (OTC Bulletin Board: MXNU; the "Company") announced today that the Company has completed the share exchange (the "Closing") pursuant to an Agreement and Plan of Reorganization with American Spring Pharmaceutical, Inc., a Delaware corporation ("ASPI"). Pursuant to the Agreement, ASPI transferred 100% of the issued and outstanding shares of Gansu Biology Science and Technology Stock Co., Ltd ("GDBS") to the Company in exchange for 20,000,000 shares of the Company's common stock.

All of the present officers and directors of the Company resigned and Mr. Qi Jinjun, the Chairman and CEO of GDBS, became the sole officer and director of the Company.

"The completion of the share exchange is a great milestone in the development of GDBS; it symbolizes the first step of GDBS to become a truly global player in the fertilizer additive and livestock feed market," remarked Mr. Qi Jinjun. "In the future, we will continue to work hard and reaffirm our commitment to providing high quality fertilizer additives and animal feed for agricultural use."

ASPI, through its wholly owned operating subsidiary Gansu Dasheng Biology Science and Technology Stock Co., Ltd. (GDBS), a limited liability corporation organized under the laws of the People's Republic of China ("PRC"), engages in the development, production and distribution of additives for fertilizers and animal feed that have been enhanced through the addition of bacteria.

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, and other risks described in statements filed from time to time with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the Company, are expressly qualified by the cautionary statements that may accompany the forward-looking statements. In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

For more information, please contact:

Peter D. Zhou

Tel: +1-212-232-0120

SOURCE Max Nutrition, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Healionics Corporation Completes Series A Financing
2. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
3. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
4. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
5. Quintiles Completes Previously Announced New Investor Partnership, Co-Led by Founder, Chairman and CEO Dennis Gillings, Bain Capital, TPG and 3i
6. CNS Response, Inc Completes Neuro-Therapy Clinic Acquisition; Names Daniel A. Hoffman, MD Chief Medical Officer
7. Abington Memorial Hospital Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
8. China Medical Technologies Completes Acquisition of BBE
9. Boston Scientific Completes Sale of Cardiac Surgery and Vascular Surgery Businesses
10. Boston Scientific Completes Sale of Auditory Business and Drug Pump Development Program
11. Pharmos Corporation Completes Initial Closing of Private Placement
Post Your Comments:
(Date:6/24/2016)... ... 2016 , ... While the majority of commercial spectrophotometers and fluorometers use the ... models are higher end machines that use the more unconventional z-dimension of 20mm. ... the bottom of the cuvette holder. , FireflySci has developed several Agilent flow ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
(Date:6/2/2016)... Perimeter Surveillance & Detection Systems, ... Infrastructure, Support & Other Service  The latest ... comprehensive analysis of the global Border Security market ... of $17.98 billion in 2016. Now: In ... in software and hardware technologies for advanced video surveillance. ...
(Date:5/12/2016)... , May 12, 2016 , ... published the overview results from the Q1 wave of ... recent wave was consumers, receptivity to a program where ... with a health insurance company. "We were ... share," says Michael LaColla , CEO of Troubadour ...
(Date:4/26/2016)... and LONDON , April ... part of EdgeVerve Systems, a product subsidiary of ... today announced a partnership to integrate the Onegini ...      (Logo: ) ... their customers enhanced security to access and transact ...
Breaking Biology News(10 mins):